B.S.P., Ph.D.
Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, UBC
Rm 4110 – 2405 Wesbrook Mall
Vancouver, BC V6T 1Z3
phone: 6048273397

Larry received his B.S.P. in 1986 from the University of Saskatchewan and his Ph.D. in the Department of Health Care and Epidemiology at the University of British Columbia in 2002. He then completed a 2-year post-doctoral fellowship in health economics with Dr. Bernie O’Brien at McMaster University. Larry is an Associate Professor in the Faculty of Pharmaceutical Sciences and is the Associate Director of CORE. He is a Scientist at the Centre for Health Evaluation and Outcomes Sciences at Providence Health, an Associate of the School of Population and Public Health, and was admitted as a Scholar in the Peter Wall Institute for Advance Studies at UBC. He is a Michael Smith Foundation for Health Research Scholar and a Canadian Institutes of Health Research New Investigator.

Larry has more the 180 peer-reviewed publications, book chapters, and research abstracts. He was appointed as the Chair of the Health Canada Special Advisory Committee on Nonprescription Drugs, and was appointed to the Special Advisory Committee to the Respiratory and Allergy Therapies division of Health Canada, the BC Ministry of Health Services Expensive Drugs for Rare Diseases committee, and the BC PharmaNet Data Stewardship Committee. His primary research interests are in the areas of risk-benefit analysis, pharmacoepidemiology,health economics and policy making for drugs for rare diseases.

PharmD Teaching Award, Faculty of Pharmaceutical Sciences, UBC, 2013
Publication Award – Research Article, Canadian Society of Hospital Pharmacists – BC Branch, 2012; Early Career Scholar, Peter Wall Institute for Advanced Studies, 2011; Specialties in Pharmacy Practice Award, Canadian Society of Hospital Pharmacists, 2008; New Investigator Award, Canadian Institutes of Health Research, 2006; Career Scholar Award, Michael Smith Foundation for Health Research, 2005; Teaching Scholarship, Faculty Certificate Program in Advanced and Higher Education, UBC, 200

1. Sadatsafavi M, Lynd LD, FitzGerald JM. Post-hospital syndrome in adults with asthma: a case-crossover study. Allergy Asthma Clin Immunol 2013; Accepted with minor revisions, October 2013.
2. Najafzadeh M, Johnston MK, Peakcock JS, Connors MJ, Marra MA, Lynd LD, Marra CA. Genomic testing to determine drug response: measuring preferences of the public and patients using a discrete choice experiment. BMC Health Serv Res 2013 Oct 31;13(1):454. [Epub ahead of print]
3. Davis EM, Lynd LD, Grubisic M, Kopec JA, Sayre EC, Cibere J, Esdaile J, Marra CA. Responsiveness of health state utility values in knee osteoarthritis. J Rheumatol. 2013 Nov 1. [Epub ahead of print]
4. Bashir J, Cowan S, Raymakers A, Yamashita M, Danter M, Krahn A, Lynd LD. A cost-effectiveness analysis of a proactive management strategy for the Sprint Fidelis recall: a probabilistic decision analysis model. Heart Rhythm , 2013 Dec;10(12):1761-7. PMID: 24076445.
5. Sweeney K, Grubisic M, Marra CA, Kendall R, Li L, Lynd LD. Comparison of HRQL between unicompartmental knee arthroplasty and total knee arthroplasty for the treatment of osteoarthritis. J Arthroplasty 2013. Accepted May 2013.
6. Sadatsafavi M, FitzGerald JM, Marra CA, Lynd LD. Dispensation of long-acting beta agonists with or without inhaled corticosteroids and risk of asthma-related hospitalisation: a population-based study. Thorax. 2013 Nov 26. doi: 10.1136/thoraxjnl-2013-2013-203998. [Epub ahead of print]. PMID: 24281327
7. Chen W, FitzGerald JM, Rousseau R, Lynd LD, Tan WC, Sadatsafavi M. Complementary and alternative asthma treatments and their association with asthma control: a population-based study. BMJ Open 2013;3:e003360. doi :10.1136/bmjopen-2013-003360.
8. Marra CA, Davis EM, Lynd LD, Grubisic M, Kopec JA, Sayre EC, Cibere J, Esdaile JM. Responsiveness of health state utility values in knee osteoarthritis. Journal of Rheumatology. Accepted, August 2013.
9. Cloutier A-M, Greenfield B, Lavoie A, Lynd LD, Tournier M, Brabant M-J, Moride Y. Effectiveness of risk communication interventions on the medical follow-up of youth treated with antidepressants. Psychiatry Research 2013; 209(3): 471-8.
10. Sadatsafavi M, Lynd LD, Marra CA, Bedouch P, FitzGerald M. Comparative outcomes of leukotriene receptor antagonists and long-acting beta-agonists as add-on therapy in asthma: a population-based study. J Allerg Asthma Clin Imunol 2013; 132(1): 63-9.
11. Sadatsafavi M, FitzGerald JM, Marra CA, Lynd LD. Costs and health outcomes associated with primary versus secondary care after an asthma-related hospitalization, a population-based study. CHEST 2013; 144(2): 428-35.
12. Bedouch P, Marra CA, FitzGerald JM, Sadatsafavi M, Lynd LD. Trends in Asthma-Related Direct Medical Costs from 2002 to 2007 in British Columbia, Canada: A Population Based-Cohort Study. PLoS ONE 2102; 7(12): e50949. doi:10.1371/journal.pone.0050949.
13. Najafzadeh M, Marra CA, Lynd LD, Wiseman SM. Cost-effectiveness of using a molecular diagnostic test to improve pre-operative diagnosis of thyroid cancer. Value Health. 2012 Dec;15(8):1005-13.
14. Sadatsafavi M, Marra CA, Marra F, Moran O, FitzGerald JM, Lynd LD. A quantitative benefit risk analysis if isoniazid (INH) for treatment of latent tuberculosis infection (LTBI) using incremental net-benefit framework. Value in Health 2012; 16(1): 66-75.
15. Najafzadeh M, Marra CA, Lynd LD, Sadatsafavi M, FitzGerald JM, McManus B, Sin D. Future impact of Various Interventions on the burden of COPD in Canada: A dynamic population model. PlosOne. 2012;7(10): e46746. doi:10.1371/journal.pone.0046746. Epub 2012 Oct 11.
16. Almeida FR, Henrich N, Marra C, Lynd LD, Lowe AA, Tsuda H, Fleetham JA, Pliska B, Ayas N. Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. Sleep Breath 2013; 17(2): 659-66.
17. Lau M, Colley L, Willett B, Lynd LD. Employee’s preferences for access to Mindfulness-based Cognitive Therapy to reduce the risk of depressive relapse – a discrete choice experiment. Mindfulness 2102; 3 (4): 318-26.
18. Marra CA, Lynd LD, Colley L, Harvard SS, Lacaille D, Schwenger E, Anis AH, Esdaile JM. Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. J Rheumatol. 2012; 39(5): 910-5.
19. Marra CA, Lynd LD, Grindrod KA, Joshi P, Isakovic A. Evaluating the labour costs associated with pharmacy adaptation services in British Columbia. Can Pharm J 2012; 145(2): 78-82. 
20. Najafzadeh M, Lynd LD, Davis JC, Bryan S, Anis A, Marra M, Marra CA. Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment. Genet Med 2012; 14(5): 520-6.

PHAR 456
PHAR 506
PHAR 384
HCEP 541
DPAS 410
ECON 384

Graduate Students
Clean MacHold, MSc
Katelyn Verstraten, MSc
Celestin Hategekimana, MSc
Pardis Lakzadeh, MSc
Elizabeth Eilson, PhD (Co-Supervisor)
Alberto Mendoza-Galina, MA (Co-Supervisor)
Keith Rozendal, MA (C-Supervisor)
Adam Raymakers, PhD
Shirin Rizzardo, MSc
Lilla Roy, MSc
I fan Kuo, MSc (Co-Supervisor)
Katie Sweeney, MSc
Belinda Chan, MSc
Camilla Guimaraes, PhD
Kelly Grindrod, MSc (Co-Supervisor)
Helen McTaggart-Cowan, MSc (Co-Supervisor)

My primary areas of scholarly interest in the conduct of state of the art outcomes research and epidemiologic studies including cost-effectiveness analysis and therapeutic risk benefit analysis using state-of-the-art computer simulation modeling techniques (including decision analysis, discrete event simulation, Monte Carlo simulation, Markov modeling), measurement of health related quality of life and patient’s preferences, and pharmacoepidemiology. One of my primary research objectives is to be involved specifically in research that will ultimate translate into improved patient outcomes, or be integrated into the decision-making process.

One of my primary disease areas of interest is in respiratory diseases, specifically asthma and COPD. Because the evaluation of health outcomes has no geographic or disease-specific boundaries, I have also become involved in a number of international studies that have the potential to influence policy in these countries.

Finally, through my involvement in the BC Ministry of Health Expensive Drug for Rare Diseases advisory committee, to which I was appointed for a second term for my health economics expertise, I have identified significant knowledge gaps relating to policy and decision-making association with orphan drugs, and expensive drugs for rare diseases. As such, I was successful in receiving a CIHR team grant, as the PI, for a national, multi-disciplinary team of economics, epidemiologists, policy research, ethicists, lawyers, clinicians, and knowledge users, to develop new knowledge relating to funding and reimbursement of expensive drugs for rare diseases.